Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3372946 | 0.86 | IDO1 (0.43) | IDO1TDO2HTTCFTROPRL1 | |
| SCHEMBL3375814 | 0.86 | IDO1 (0.43) | IDO1TDO2HTTCFTROPRL1 | |
| SCHEMBL5117761 | 0.86 | IDO1 (0.43) | IDO1TDO2HTTCFTROPRL1 | |
| SCHEMBL5117680 | 0.86 | IDO1 (0.43) | IDO1TDO2HTTCFTROPRL1 | |
| SCHEMBL11604556 | 0.86 | IDO1 (0.43) | IDO1TDO2HTTCFTROPRL1 | |
| SCHEMBL8038938 | 0.83 | CFTR (0.46) | IDO1TDO2HTTCFTROPRL1 | |
| SCHEMBL29930172 | 0.83 | CFTR (0.46) | IDO1TDO2HTTCFTROPRL1 | |
| SCHEMBL608330 | 0.81 | CFTR (0.41) | IDO1TDO2HTTCFTROPRL1 | |
| SCHEMBL286556 | 0.79 | HTT (0.46) | IDO1TDO2HTTCFTROPRL1 | |
| SCHEMBL1328402 | 0.79 | HTT (0.46) | IDO1TDO2HTTCFTROPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027091-A | Preparation method of treprostinil and intermediate thereof | 广州楷石医药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2020186504-A1 | A NEW TYPE OF ANTITUMOR COMPOUNDS: DERIVATIVES OF 7-PROPANAMIDE SUBSTITUTED BENZOXABOROLE | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2020-09-24 | — | — | WO | disclosed |
| WO-2019153324-A1 | DERIVATIVES OF 7-FATTY ACID SUBSTITUTED BENZOXABOROLE AND THEIR PREPARATION AND USE | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2019-08-15 | — | — | WO | disclosed |
| EP-2980116-B1 | HYDROPHILIC POLYMER DERIVATIVE HAVING BENZYLIDENE ACETAL LINKER | NOF CORP (JP) | 2017-07-26 | — | — | EP | disclosed |
| EP-3070085-A1 | FLAP MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-09-21 | — | — | EP | disclosed |
| US-7550451-B2 | Progesterone receptor modulators with increased antigonadotropic activity for female birth control and hormone replacement therapy | BAYER SCHERING PHARMA AG (DE) | 2009-06-23 | — | — | US | disclosed |
| EP-1525215-B1 | PROGESTERONE RECEPTOR MODULATORS HAVING AN INCREASED ANTIGONADOTROPIC ACTIVITY FOR USE IN FEMALE FERTILITY TESTING AND HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| EP-1525215-A1 | PROGESTERONE RECEPTOR MODULATORS HAVING AN INCREASED ANTIGONADOTROPIC ACTIVITY FOR USE IN FEMALE FERTILITY TESTING AND HORMONE REPLACEMENT THERAPY | Schering Aktiengesellschaft (DE) | 2005-04-27 | — | — | EP | disclosed |
| US-20050026891-A1 | Progesterone receptor modulators with increased antigonadotropic activity for female birth control and hormone replacement therapy | BAYER SCHERING PHARMA AG (DE) | 2005-02-03 | — | — | US | disclosed |
| WO-2004014935-A1 | PROGESTERONE RECEPTOR MODULATORS HAVING AN INCREASED ANTIGONADOTROPIC ACTIVITY FOR USE IN FEMALE FERTILITY TESTING AND HORMONE REPLACEMENT THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-19 | — | — | WO | disclosed |
| EP-0857171-A2 | IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-08-12 | — | — | EP | disclosed |
| WO-1997015555-A2 | IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026891-A1 | Progesterone receptor modulators with increased antigonadotropic activity for female birth control and hormone replacement therapy | LHCGR, PGR, GNRHR | IDO1 3271/4885TDO2 1335/4885HTT 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.